Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

4th HIV Research for Prevention Conference (HIVR4P // Virtual)—Rapid Recap

January 27-28 and February 3-4, 2021
Hear insights from Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, on some of the most important new data reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, implantable options, multipurpose prevention strategies, and key aspects of PrEP implementation
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: February 18, 2021

In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.  

Presenter:

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD 
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021

Nelly Mugo, MBChB, MMed, MPH Released: April 15, 2021

Expert commentary from CCO detailing the use of HIV-ASSIST to support ART selection in a socially- and medically-complex, treatment-experienced patient with HIV

person default Matthew M. Hamill, MBChB, MPH, MSc, PhD Released: April 9, 2021

CCO expert commentary by Dr Monica Gandhi on key considerations with long-acting pre-exposure prophylaxis based on data presented at CROI 2021

Monica Gandhi, MD, MPH Released: April 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue